{
    "xml": "<topic id=\"PHP81552\" outputclass=\"clinicalMedicinalProductInformation\" type=\"clinicalMedicinalProductInformation\" namespace=\"/clinical-medicinal-product-information/phyllocontin-continus-forte\" basename=\"phyllocontin-continus-forte\" title=\"Phyllocontin Continus Forte\">\n<title>Phyllocontin Continus<tm tmtype=\"reg\"/> Forte</title>\n<topic id=\"PHP82986\" outputclass=\"indicationsAndDose\" rev=\"1.20\" parent=\"/clinical-medicinal-product-information/phyllocontin-continus-forte\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Reversible airways obstruction</p>\n<p outputclass=\"therapeuticIndication\">Severe acute asthma</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth using modified-release medicines</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 350&#8239;mg twice daily for 1 week, then increased if necessary to 700&#8239;mg twice daily, increase dose according to plasma-theophylline concentration.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP82994\" outputclass=\"unlicensedUse\" rev=\"1.9\" parent=\"/clinical-medicinal-product-information/phyllocontin-continus-forte\">\n<title>Unlicensed use</title>\n<body>\n<section>\n<sectiondiv>\n<p>\n<i>Phyllocontin Continus</i>\n<tm tmtype=\"reg\"/>\n<i>Forte</i> tablets are not licensed for use in children.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP83006\" outputclass=\"prescribingAndDispensingInformation\" rev=\"1.12\" parent=\"/clinical-medicinal-product-information/phyllocontin-continus-forte\">\n<title>Prescribing and dispensing information</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">oral</ph> use</p>\n<p>\n<i>Phyllocontin Continus</i>\n<tm tmtype=\"reg\"/> Forte tablets are for smokers and other patients where theophylline half-life is shorter.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"clinicalMedicinalProductInformation\" href=\"#clinicalMedicinalProductInformation\" title=\"Clinical medicinal product information\" namespace=\"/clinical-medicinal-product-information\">Clinical medicinal product information</xref>\n</parents>\n<backlinks/>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"#clinicalMedicinalProductInformation\" href=\"#clinicalMedicinalProductInformation\" namespace=\"/clinical-medicinal-product-information\" title=\"Clinical medicinal product information\" count=\"1\" rel=\"link\">Clinical medicinal product information</xref>\n</links>\n</topic>",
    "id": "PHP81552",
    "outputclass": "clinicalMedicinalProductInformation",
    "type": "clinicalMedicinalProductInformation",
    "namespace": "/clinical-medicinal-product-information/phyllocontin-continus-forte",
    "basename": "phyllocontin-continus-forte",
    "title": "Phyllocontin Continus Forte",
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Reversible airways obstruction",
                        "html": "Reversible airways obstruction"
                    },
                    {
                        "textContent": "Severe acute asthma",
                        "html": "Severe acute asthma"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth using modified-release medicines"
                    ],
                    "textContent": "By mouth using modified-release medicines",
                    "html": "By mouth using modified-release medicines"
                },
                "adult": [
                    {
                        "textContent": "Initially 350 mg twice daily for 1 week, then increased if necessary to 700 mg twice daily, increase dose according to plasma-theophylline concentration.",
                        "html": "<p>Initially 350&#8239;mg twice daily for 1 week, then increased if necessary to 700&#8239;mg twice daily, increase dose according to plasma-theophylline concentration.</p>"
                    }
                ]
            }
        ]
    },
    "unlicensedUse": {
        "unlicensedUse": [
            {
                "type": "unlicensedUse",
                "textContent": "Phyllocontin Continus Forte tablets are not licensed for use in children.",
                "html": "<p>\n<i>Phyllocontin Continus</i>\n<tm tmtype=\"reg\"/>\n<i>Forte</i> tablets are not licensed for use in children.</p>"
            }
        ]
    },
    "prescribingAndDispensingInformation": {
        "prescribingAndDispensingInformation": [
            {
                "type": "prescribingAndDispensingInformation",
                "specificity": {
                    "textContent": "With oral use",
                    "html": "With <ph outputclass=\"route\">oral</ph> use",
                    "routes": [
                        "oral"
                    ]
                },
                "textContent": "Phyllocontin Continus Forte tablets are for smokers and other patients where theophylline half-life is shorter.",
                "html": "<p>\n<i>Phyllocontin Continus</i>\n<tm tmtype=\"reg\"/> Forte tablets are for smokers and other patients where theophylline half-life is shorter.</p>"
            }
        ]
    },
    "backlinks": {},
    "links": {
        "#clinicalMedicinalProductInformation": [
            {
                "id": "clinicalMedicinalProductInformation",
                "label": "Clinical medicinal product information",
                "type": "#clinicalMedicinalProductInformation"
            }
        ]
    }
}